Anti-EGFR Monoclonal Antibody clinical trials
Also written SCT200.
How each study uses Anti-EGFR Monoclonal Antibody is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-EGFR Monoclonal Antibody studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 3
Dragonboat Biopharmaceutical Company Limited (2) · Second Affiliated Hospital of Soochow University (1) · Fudan University (1) · Sinocelltech Ltd. (1) · Shi Yuankai (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-EGFR Monoclonal Antibody.
- Feb 2027Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid TumorsPhase 2 · Second Affiliated Hospital of Soochow University
Studies
Open first, then newest update. How each study uses Anti-EGFR Monoclonal Antibody is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid TumorsNot yet recruitingPhase 2Second Affiliated Hospital of Soochow UniversityNCT07327411Written as anti-EGFR monoclonal antibody
- A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCCCompletedPhase 1Dragonboat Biopharmaceutical Company LimitedNCT03491709Written as anti-EGFR monoclonal antibody
- Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to ErbituxCompletedPhase 1Dragonboat Biopharmaceutical Company LimitedNCT03881787Written as anti-EGFR monoclonal antibody
- Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction ChemotherapyStatus unknownPhase 2Fudan UniversityNCT04508829Written as Anti-EGFR monoclonal antibody
- Safety and Efficacy of SCT200 in Head and Neck Squamous Cell CarcinomaStatus unknownPhase 2Sinocelltech Ltd.NCT03713372Written as Anti-EGFR monoclonal antibody
- SCT200 Injection in Patients With Head and Neck Squamous Cell CarcinomaStatus unknownPhase 2Shi YuankaiNCT03744208Written as Anti-EGFR monoclonal antibody